90.73
+0.99(+1.10%)
Currency In USD
| Previous Close | 89.74 |
| Open | 88.82 |
| Day High | 93.12 |
| Day Low | 87.69 |
| 52-Week High | 105 |
| 52-Week Low | 64.11 |
| Volume | 597,785 |
| Average Volume | 482,157 |
| Market Cap | 4.4B |
| PE | -13.79 |
| EPS | -6.58 |
| Moving Average 50 Days | 93.25 |
| Moving Average 200 Days | 83.66 |
| Change | 0.99 |
If you invested $1000 in Axsome Therapeutics, Inc. (AXSM) since IPO date, it would be worth $10,381.01 as of December 22, 2024 at a share price of $90.73. Whereas If you bought $1000 worth of Axsome Therapeutics, Inc. (AXSM) shares 5 years ago, it would be worth $918.88 as of December 22, 2024 at a share price of $90.73.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in ENCORE Long-Term Phase 3 Trial in Narcolepsy
GlobeNewswire Inc.
Nov 26, 2024 12:00 PM GMT
AXS-12 statistically significantly reduced the frequency of cataplexy attacks compared to placebo (p=0.017, primary endpoint) Statistically significant improvement in cognition compared to placebo (p=0.011, NSAQ) Statistically significant improvemen
Axsome Therapeutics Presents Data from Its Leading Neuroscience Pipeline at NEI Congress 2024
GlobeNewswire Inc.
Nov 08, 2024 12:00 PM GMT
NEW YORK, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced eight presenta
Axsome Therapeutics Presents Data from Multiple Programs Spanning Its Innovative Neuroscience Portfolio at Psych Congress 2024
GlobeNewswire Inc.
Oct 29, 2024 11:00 AM GMT
NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced seven presenta